322 related articles for article (PubMed ID: 28587612)
1. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
2. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
3. Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil
Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2018 Sep; 82(3):521-532. PubMed ID: 29995186
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
5. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
[TBL] [Abstract][Full Text] [Related]
8. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
Gynecol Oncol; 2016 May; 141(2):357-363. PubMed ID: 26946092
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model.
Chen LC; Chang CH; Yu CY; Chang YJ; Wu YH; Lee WC; Yeh CH; Lee TW; Ting G
Nucl Med Biol; 2008 Nov; 35(8):883-93. PubMed ID: 19026950
[TBL] [Abstract][Full Text] [Related]
10. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
11. Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy.
Chang CH; Stabin MG; Chang YJ; Chen LC; Chen MH; Chang TJ; Lee TW; Ting G
Cancer Biother Radiopharm; 2008 Dec; 23(6):749-58. PubMed ID: 19111045
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
13. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
Moase EH; Qi W; Ishida T; Gabos Z; Longenecker BM; Zimmermann GL; Ding L; Krantz M; Allen TM
Biochim Biophys Acta; 2001 Feb; 1510(1-2):43-55. PubMed ID: 11342146
[TBL] [Abstract][Full Text] [Related]
14. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx
Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Rajamannar T
Leuk Lymphoma; 2018 Jun; 59(6):1478-1481. PubMed ID: 28994344
[No Abstract] [Full Text] [Related]
15. Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer.
S PS; Nagarkar RV; Puligundla KC; N LK; Boya RR; Patel AB; Goyal L; Thoke A; Patel JG; Mehta AO; Patel GN; Khan MA; Ahmad I
Eur J Pharm Sci; 2022 Sep; 176():106248. PubMed ID: 35777616
[TBL] [Abstract][Full Text] [Related]
16. A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx
Li Y; Qi L; Wang Y; Li Y; Lei C; Zhang Y; Cheng X; Liu J; Bai H; Zhao X; Lv S; Xiong B; Liu J; Shi Y; Zhou H; Li H; Liu L; Jiang H; Ouyang W; Li X; Li Y; Wang X
Front Oncol; 2022; 12():1070001. PubMed ID: 36605440
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice.
Gonzalez-Paz O; Polizzi D; De Cesare M; Zunino F; Bigioni M; Maggi CA; Manzini S; Pratesi G
Eur J Cancer; 2001 Feb; 37(3):431-7. PubMed ID: 11239767
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
19. The Comparison of Biodistribution, Efficacy and Toxicity of Two PEGylated Liposomal Doxorubicin Formulations in Mice Bearing C-26 Colon Carcinoma: a Preclinical Study.
Razavi-Azarkhiavi K; Jafarian AH; Abnous K; Razavi BM; Shirani K; Zeinali M; Jaafari MR; Karimi G
Drug Res (Stuttg); 2016 Jun; 66(6):330-6. PubMed ID: 27022719
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the Discriminatory Ability of Pharmacokinetic Metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin.
Hsu LF
Pharm Res; 2018 Mar; 35(5):106. PubMed ID: 29564719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
